losartan has been researched along with Complications of Diabetes Mellitus in 45 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 9.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension." | 9.14 | Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009) |
| "The study demonstrated that the combination of manidipine and delapril is as effective as losartan and hydrochlorothiazide in treatment of hypertension in type 2 diabetes." | 9.13 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Triposkiadis, F; Wenzel, RR, 2008) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 9.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 9.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "We explored the impact of baseline left ventricular hypertrophy (LVH) and losartan treatment on renal and cardiovascular (CV) events in 1,513 patients from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, which studied the effects of losartan on the progression of renal disease and/or death in patients with type 2 diabetes and nephropathy." | 9.11 | Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S, 2005) |
| "As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment." | 9.10 | Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 6.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "Electrocardiographic left ventricular hypertrophy (LVH) predicts cardiovascular morbidity and mortality, and regression of ECG LVH may predict improved prognosis in hypertensive patients." | 6.71 | Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. ( Aurup, P; Dahlof, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Nieminen, MS; Okin, PM; Snapinn, S, 2003) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 6.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| " Main outcome parameters were the systolic (SBP) and diastolic (DBP) blood pressure reduction, the rate of normalized patients at study end compared to baseline, and the number and type of adverse events (AEs)." | 5.35 | Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care. ( Bestehorn, K; Bönner, G; Jung, C; Smolka, W, 2009) |
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 5.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| "HYPOTHESIS/ INTRODUCTION: We investigated whether diabetes modified the effectiveness of renin-angiotensin-aldosterone system (RAAS) inhibition on left ventricular hypertrophy (LVH) regression in hypertensive patients in the Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial." | 5.16 | Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression. ( Appelbaum, E; Dahlof, B; Pouleur, AC; Prescott, M; Smith, B; Solomon, SD; Takeuchi, M; Vardeny, O; Verma, A, 2012) |
| "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension." | 5.14 | Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009) |
| "The study demonstrated that the combination of manidipine and delapril is as effective as losartan and hydrochlorothiazide in treatment of hypertension in type 2 diabetes." | 5.13 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Triposkiadis, F; Wenzel, RR, 2008) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 5.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.12 | The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. ( Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA, 2007) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 5.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "We explored the impact of baseline left ventricular hypertrophy (LVH) and losartan treatment on renal and cardiovascular (CV) events in 1,513 patients from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, which studied the effects of losartan on the progression of renal disease and/or death in patients with type 2 diabetes and nephropathy." | 5.11 | Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S, 2005) |
| "As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment." | 5.10 | Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy." | 4.82 | Implications of the LIFE trial. ( Lim, HS; Lip, GY; Nadar, S, 2003) |
| "Here, we show that diabetic rats exhibit depression-like behaviour, which can be therapeutically reversed by losartan." | 3.91 | Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling. ( Balogh, DB; Barczi, A; Denes, A; Farkas, T; Fekete, A; Hodrea, J; Hosszu, A; Lenart, L; Lenart, N; Szabo, AJ; Szigeti, K, 2019) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 2.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "Electrocardiographic left ventricular hypertrophy (LVH) predicts cardiovascular morbidity and mortality, and regression of ECG LVH may predict improved prognosis in hypertensive patients." | 2.71 | Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. ( Aurup, P; Dahlof, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Nieminen, MS; Okin, PM; Snapinn, S, 2003) |
| "Among the 1,281 patients with incident cancer and 5,104 controls, 333 (26." | 2.47 | Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. ( Chang, CH; Lai, MS; Lin, JW; Wu, LC, 2011) |
| "In studies of dementias and Alzheimer's disease (AD), some studies have shown that antihypertensive drugs, including angiotensin-converting enzyme inhibitors, have some moderate effects on cognitive decline, but that the angiotensin receptor antagonist losartan has a significantly beneficial effect." | 2.42 | Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. ( Gard, PR, 2004) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 2.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| "Arterial hypertension is a major risk factor for microangiopathic diabetic complications and associated with an increased cardiovascular morbidity and mortality." | 2.41 | [Angiotensin II type-1 receptor antagonists and diabetes mellitus]. ( Schernthaner, G; Schnack, C, 2001) |
| " Main outcome parameters were the systolic (SBP) and diastolic (DBP) blood pressure reduction, the rate of normalized patients at study end compared to baseline, and the number and type of adverse events (AEs)." | 1.35 | Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care. ( Bestehorn, K; Bönner, G; Jung, C; Smolka, W, 2009) |
| "Losartan prevented an increase in BP and SGLT2 expression in diabetic rats." | 1.35 | Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. ( Bautista, R; Escalante, B; Franco, M; Osorio, H; Rios, A; Santamaría, J, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 38 (84.44) | 29.6817 |
| 2010's | 7 (15.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oltulu, F | 1 |
| Buhur, A | 1 |
| Gürel, Ç | 1 |
| Kuşçu, GC | 1 |
| Dağdeviren, M | 1 |
| Karabay Yavaşoğlu, NÜ | 1 |
| Köse, T | 1 |
| Yavaşoğlu, A | 1 |
| Kim, JY | 1 |
| Son, JW | 1 |
| Park, S | 1 |
| Yoo, TH | 1 |
| Kim, YJ | 1 |
| Ryu, DR | 1 |
| Chin, HJ | 1 |
| Shree, J | 1 |
| Choudhary, R | 1 |
| Bodakhe, SH | 1 |
| Lenart, L | 1 |
| Balogh, DB | 1 |
| Lenart, N | 1 |
| Barczi, A | 1 |
| Hosszu, A | 1 |
| Farkas, T | 1 |
| Hodrea, J | 1 |
| Szabo, AJ | 1 |
| Szigeti, K | 1 |
| Denes, A | 1 |
| Fekete, A | 1 |
| Senador, D | 1 |
| Kanakamedala, K | 1 |
| Irigoyen, MC | 1 |
| Morris, M | 1 |
| Elased, KM | 1 |
| Bönner, G | 1 |
| Smolka, W | 1 |
| Jung, C | 1 |
| Bestehorn, K | 1 |
| Kinouchi, K | 1 |
| Ichihara, A | 1 |
| Sakoda, M | 1 |
| Kurauchi-Mito, A | 1 |
| Itoh, H | 1 |
| Osorio, H | 1 |
| Bautista, R | 1 |
| Rios, A | 1 |
| Franco, M | 1 |
| Santamaría, J | 1 |
| Escalante, B | 1 |
| Fogari, R | 2 |
| Mugellini, A | 1 |
| Circelli, M | 1 |
| Cremonesi, G | 1 |
| Chang, CH | 1 |
| Lin, JW | 1 |
| Wu, LC | 1 |
| Lai, MS | 1 |
| Vardeny, O | 1 |
| Pouleur, AC | 1 |
| Takeuchi, M | 1 |
| Appelbaum, E | 1 |
| Verma, A | 1 |
| Prescott, M | 1 |
| Smith, B | 1 |
| Dahlof, B | 9 |
| Solomon, SD | 1 |
| Malik, RA | 1 |
| Eguchi, K | 1 |
| Kario, K | 1 |
| Shimada, K | 1 |
| Karpov, IuA | 1 |
| Ibsen, H | 5 |
| Lindholm, LH | 6 |
| Pedersen, OL | 1 |
| Kjeldsen, S | 1 |
| Ye, G | 1 |
| Metreveli, NS | 1 |
| Ren, J | 1 |
| Epstein, PN | 1 |
| Zukowska-Szczechowska, E | 1 |
| Gosek, K | 1 |
| Grzeszczak, W | 1 |
| Nadar, S | 1 |
| Lim, HS | 1 |
| Lip, GY | 1 |
| Okin, PM | 2 |
| Devereux, RB | 7 |
| Jern, S | 2 |
| Kjeldsen, SE | 6 |
| Julius, S | 6 |
| Nieminen, MS | 4 |
| Snapinn, S | 3 |
| Harris, KE | 3 |
| Aurup, P | 2 |
| Edelman, JM | 4 |
| Borch-Johnsen, K | 1 |
| Olsen, MH | 1 |
| Wachtell, K | 2 |
| Baumgart, P | 2 |
| Diener, HC | 1 |
| Wargo, KA | 1 |
| Chong, K | 1 |
| Chan, EC | 1 |
| Winkler, G | 1 |
| Jermendy, G | 1 |
| Matos, L | 1 |
| Gard, PR | 1 |
| Nomura, S | 1 |
| Shouzu, A | 1 |
| Omoto, S | 1 |
| Nishikawa, M | 1 |
| Iwasaka, T | 1 |
| Kohno, M | 1 |
| Lyle, PA | 2 |
| Kizer, JR | 2 |
| Beevers, G | 3 |
| de Faire, U | 3 |
| Fyhrquist, F | 3 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 3 |
| Omvik, P | 3 |
| Oparil, S | 3 |
| Wedel, H | 3 |
| Snapinn, SM | 2 |
| Boner, G | 1 |
| Cooper, ME | 1 |
| McCarroll, K | 1 |
| Brenner, BM | 1 |
| de Zeeuw, D | 1 |
| Kowey, PR | 1 |
| Shahinfar, S | 1 |
| Dickson, T | 1 |
| Crow, RS | 1 |
| Parving, HH | 1 |
| Gurusamy, N | 1 |
| Watanabe, K | 1 |
| Ma, M | 1 |
| Prakash, P | 1 |
| Hirabayashi, K | 1 |
| Zhang, S | 1 |
| Muslin, AJ | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Gerdts, E | 1 |
| Fossum, E | 1 |
| Gleim, GW | 1 |
| Brady, WE | 1 |
| Hille, DA | 1 |
| Roca-Cusachs, A | 1 |
| Schmieder, RE | 1 |
| Triposkiadis, F | 1 |
| Wenzel, RR | 1 |
| Laurent, S | 1 |
| Kohlmann, O | 1 |
| Arrick, DM | 1 |
| Sharpe, GM | 1 |
| Sun, H | 1 |
| Mayhan, WG | 1 |
| Paul, B | 1 |
| Sapra, B | 1 |
| Maheshwari, S | 1 |
| Goyal, RK | 1 |
| Schnack, C | 1 |
| Schernthaner, G | 1 |
| Kristiansson, K | 2 |
| Edelman, J | 1 |
| Khan, MA | 1 |
| Morgan, RJ | 1 |
| Mikhailidis, DP | 1 |
| Studney, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02620306] | Phase 3 | 351 participants (Actual) | Interventional | 2016-02-11 | Completed | ||
| ANGIOTENSIN AGENTS AND REDUCTION OF THE PRESCRIPTION OF ANTIDEPRESSANT DRUGS: A RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATA[NCT04899206] | 120 participants (Anticipated) | Observational [Patient Registry] | 2021-04-12 | Active, not recruiting | |||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry[NCT03219632] | 72 participants (Actual) | Observational [Patient Registry] | 2012-06-05 | Completed | |||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for losartan and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Comp | 2011 |
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2011 |
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2002 |
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
[Antihypertensive treatment in patients with diabetes mellitus].
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Bosentan; Diabetes Complications; Endothel | 2002 |
Implications of the LIFE trial.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
[Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2003 |
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.
Topics: Aging; Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2004 |
[Hypertension in patients with cardiac hypertrophy].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2004 |
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2004 |
Update on the efficacy of angiotensin receptor blockers in treatment of hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Captopril; Diabetes Complications; Drug E | 2005 |
Role of losartan therapy in the management of diabetic hypertension.
Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypertension; Losartan; Randomized Controlled Tri | 2000 |
[Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
14 trials available for losartan and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials, Phase III | 2017 |
Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension.
Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Asian People; Blood Pressure; Cross-Over S | 2009 |
Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.
Topics: Aldosterone; Amides; Antihypertensive Agents; Biomarkers; Blood Pressure; Diabetes Complications; Fe | 2012 |
Prevention of cardiovascular morbidity with angiotension receptor blockade: life after LIFE.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Clinical Pr | 2002 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabe | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus.
Topics: Aged; Angiotensin Receptor Antagonists; Biomarkers; Blood Pressure; Chemokines; Diabetes Complicatio | 2004 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2005 |
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Topics: Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Diab | 2005 |
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Diabetes Mellitu | 2006 |
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Compli | 2007 |
Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Co | 2008 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
17 other studies available for losartan and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-κB expressions
Topics: Animals; Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus, Experimental; Liver Dis | 2019 |
Losartan delays the progression of streptozotocin-induced diabetic cataracts in albino rats.
Topics: Administration, Oral; Administration, Topical; Aldehyde Reductase; Angiotensin II Type 1 Receptor Bl | 2019 |
Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Behavior, Animal; | 2019 |
Cardiovascular and autonomic phenotype of db/db diabetic mice.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Nervous System; B | 2009 |
Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Complications; Drug Therapy, Com | 2009 |
Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Experim | 2009 |
No morbidity-mortality. Commentary.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Diabe | 2002 |
Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Calcium; Diabetes Complications; Diabetes | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Co | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Acute renal failure secondary to angiotensin II receptor blockade in a patient with bilateral renal artery stenosis.
Topics: Acute Kidney Injury; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Con | 2003 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol.
Topics: 14-3-3 Proteins; Angiotensin II; Animals; Apoptosis; Blood Glucose; Body Weight; Cardiomegaly; Cardi | 2006 |
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Losartan improves impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in type 1 diabetic rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arterioles; Cerebral Arteries; Cerebrovascular Dis | 2008 |
The choice of antihypertensive drugs in patients with erectile dysfunction.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Doxazosin; Erectile Dysfunction; Humans; Hype | 2002 |